These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 22265062)

  • 1. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
    Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
    Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M; Moriwaki K; Noto S; Takiguchi T
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
    Mueller D; Gandjour A
    Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
    Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
    J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
    Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
    Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
    Schwenkglenks M; Lippuner K
    Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
    Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
    J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.
    Hiligsmann M; Gathon HJ; Bruyère O; Ethgen O; Rabenda V; Reginster JY
    Value Health; 2010; 13(4):394-401. PubMed ID: 20102558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
    Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
    Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
    Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
    Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
    Mueller D; Gandjour A
    Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.